Alumis Inc.

Company Overview

Alumis Inc. (NASDAQ: ALMS) is a clinical-stage biopharmaceutical company focused on developing precision immunology therapies for immune-mediated diseases. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on oral therapies designed to selectively modulate immune signaling pathways. Its lead programs are centered on tyrosine kinase 2 (TYK2) inhibition and other targeted approaches intended to improve efficacy and safety profiles relative to existing immunology treatments.

The company’s principal revenue and value drivers are its clinical-stage drug candidates and strategic collaborations tied to research and development. Alumis has focused on diseases such as psoriasis, systemic lupus erythematosus, and other chronic inflammatory conditions where immune dysregulation plays a central role. The company evolved from assets and scientific programs associated with Foresite Labs, which incubated the business before its transition into an independent publicly traded biotechnology company. Alumis positions itself around data-driven drug discovery and precision medicine approaches intended to identify patient populations most likely to benefit from targeted therapies.